Chronic Lymphocytic Leukemia | Specialty

Dr. Raphael on the Treatment Landscape of CLL

March 3rd 2020

Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.

CLL Treatment in Community Oncology

February 29th 2020

Sequencing Therapy in CLL: BTK and BCL2 Inhibitors

February 29th 2020

BTK Inhibitors in CLL: Treatment Selection

February 29th 2020

Second-Generation BTK Data in CLL

February 29th 2020

Evolution of BTK Inhibitors in CLL

February 29th 2020

BTK and BCL-2 Inhibitors Reach New Milestones in CLL

February 26th 2020

Michael Choi, MD, sheds light on the data with BTK and BCL-2 inhibitors in CLL and shares ongoing research being done with PI3K inhibitors and CAR T-cell therapy in the relapsed/refractory setting.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

February 20th 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Expert Highlights Evolution of BTK Inhibitors in CLL

February 18th 2020

Alexey V. Danilov, MD, PhD, discusses the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.

Dr. Fakhri on Ongoing Clinical Trials in CLL

February 18th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses ongoing clinical trials in chronic lymphocytic leukemia (CLL).

Dr. Awan on Time-Limited Treatments in CLL

February 14th 2020

Farrukh Awan, MD, discusses the need for time-limited treatments in patients with chronic lymphocytic leukemia.

CD19-Directed CAR-NK Cell Therapy Elicits Responses in Non-Hodgkin Lymphoma and CLL

February 13th 2020

Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Siddiqi on the Results of the TRANSCEND CLL 004 Trial in CLL

February 11th 2020

Tanya Siddiqi, MD, discusses the results of the TRANSCEND CLL 004 trial.

Dr. Furman on Acalabrutinib Monotherapy in CLL

February 11th 2020

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Sharman on Remaining Challenges With BTK Inhibitors in CLL

February 7th 2020

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.

Dr. Awan on the Role of Chemotherapy in CLL

February 5th 2020

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Woyach on the Design of the Ongoing Alliance A041702 Trial in CLL

February 5th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).

Dr. Davids on Exciting Data With Acalabrutinib in CLL

February 4th 2020

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Novel Agents, Approaches Advancing CLL Paradigm

February 3rd 2020

Farrukh Awan, MD, discusses the introduction of acalabrutinib into chronic lymphocytic leukemia as well as other paradigm-shifting advances with BTK inhibitors, novel combinations, and emerging agents.